I will go one step further - and suggest it is apparent now in my view, as to why paxalisib did not go forward to the next stage in GBM AGILE.
Paxalisib hobbled in all their GBM studies so far - without this strong emphasis to have patients cut insulin levels.
- how about come on with your views on something just a little more technical here this time.
Lets here it - what have others got.
- Forums
- ASX - By Stock
- KZA
- GBM PAXALISIB ESMO 09/09/2022
GBM PAXALISIB ESMO 09/09/2022, page-15
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online